Malcisbo develops novel carbohydrate-based vaccines for human and animal health. Their focus is on parasitic diseases, on human food safety and on zoonotic diseases. The company has developed its proprietary target discovery platform to identify carbohydrates as vaccine targets. Combined with their glycoengineering technologies, novel and efficient glycoconjugate vaccines are being developed. Malcisbo is developing a strong pipeline of novel vaccine products coming out this platform for unmet needs in human and veterinary medicine targeting large markets. It is Malcisbo’s goal to develop affordable vaccines to protect people in underdeveloped areas against parasitic worm infections (e.g., helminthic infections by hookworm, filaria or schistosoma).